Name |
Number of Publications
|
Most Recent Publication
|
Publications by All Authors
|
Concept Score
|
Why?
|
---|
Influenza Vaccines | 105 | 2025 | 482 | 14.750 |
Why?
|
Influenza, Human | 114 | 2025 | 662 | 14.480 |
Why?
|
Influenza A Virus, H1N1 Subtype | 42 | 2024 | 178 | 6.890 |
Why?
|
Vaccination | 88 | 2025 | 964 | 5.560 |
Why?
|
Influenza A Virus, H3N2 Subtype | 47 | 2024 | 115 | 4.040 |
Why?
|
Seasons | 51 | 2025 | 312 | 3.240 |
Why?
|
Hospitalization | 58 | 2025 | 1790 | 3.110 |
Why?
|
Health Personnel | 13 | 2022 | 509 | 2.450 |
Why?
|
Influenza B virus | 29 | 2024 | 87 | 2.260 |
Why?
|
United States | 106 | 2025 | 10936 | 1.910 |
Why?
|
Vaccines, Inactivated | 23 | 2024 | 145 | 1.860 |
Why?
|
Antibodies, Viral | 18 | 2025 | 1154 | 1.790 |
Why?
|
Adult | 129 | 2025 | 29692 | 1.660 |
Why?
|
Emergency Responders | 5 | 2022 | 17 | 1.480 |
Why?
|
Outpatients | 17 | 2024 | 257 | 1.400 |
Why?
|
Respiratory Tract Infections | 10 | 2023 | 274 | 1.320 |
Why?
|
Adolescent | 90 | 2025 | 19373 | 1.310 |
Why?
|
Influenza A virus | 13 | 2025 | 139 | 1.220 |
Why?
|
Humans | 205 | 2025 | 125392 | 1.210 |
Why?
|
Population Surveillance | 15 | 2025 | 389 | 1.140 |
Why?
|
Young Adult | 59 | 2025 | 9069 | 1.110 |
Why?
|
Middle Aged | 85 | 2025 | 26990 | 1.080 |
Why?
|
Aged | 78 | 2025 | 19896 | 1.050 |
Why?
|
Vaccines, Combined | 12 | 2024 | 39 | 1.010 |
Why?
|
Case-Control Studies | 28 | 2025 | 3306 | 0.960 |
Why?
|
Viral Load | 4 | 2023 | 389 | 0.960 |
Why?
|
Vaccines, Synthetic | 16 | 2023 | 316 | 0.960 |
Why?
|
Child, Preschool | 61 | 2025 | 14030 | 0.880 |
Why?
|
Prospective Studies | 26 | 2025 | 6168 | 0.860 |
Why?
|
Vaccine Potency | 6 | 2020 | 9 | 0.840 |
Why?
|
Male | 98 | 2025 | 61663 | 0.820 |
Why?
|
Smallpox Vaccine | 1 | 2023 | 37 | 0.810 |
Why?
|
Female | 101 | 2025 | 66885 | 0.800 |
Why?
|
Ambulatory Care | 11 | 2024 | 390 | 0.790 |
Why?
|
Antibody Formation | 5 | 2024 | 266 | 0.730 |
Why?
|
Child | 68 | 2025 | 24436 | 0.730 |
Why?
|
Spike Glycoprotein, Coronavirus | 6 | 2025 | 188 | 0.730 |
Why?
|
Occupations | 1 | 2021 | 22 | 0.720 |
Why?
|
Hemagglutination Inhibition Tests | 6 | 2024 | 114 | 0.710 |
Why?
|
Occupational Diseases | 1 | 2021 | 75 | 0.690 |
Why?
|
Respiratory Syncytial Virus Infections | 4 | 2025 | 345 | 0.680 |
Why?
|
Infant | 45 | 2025 | 12518 | 0.630 |
Why?
|
Pneumonia | 1 | 2022 | 325 | 0.600 |
Why?
|
Immunocompromised Host | 5 | 2024 | 294 | 0.590 |
Why?
|
RNA, Messenger | 18 | 2024 | 2820 | 0.580 |
Why?
|
Vaccines, Attenuated | 12 | 2018 | 175 | 0.550 |
Why?
|
Immunogenicity, Vaccine | 3 | 2025 | 106 | 0.520 |
Why?
|
Dose-Response Relationship, Immunologic | 1 | 2016 | 108 | 0.500 |
Why?
|
Dementia | 1 | 2020 | 452 | 0.490 |
Why?
|
Immunization, Secondary | 5 | 2022 | 104 | 0.480 |
Why?
|
Social Class | 2 | 2013 | 190 | 0.480 |
Why?
|
Emergency Service, Hospital | 12 | 2024 | 1070 | 0.470 |
Why?
|
Aged, 80 and over | 23 | 2025 | 6607 | 0.440 |
Why?
|
Pandemics | 5 | 2023 | 1115 | 0.410 |
Why?
|
Cohort Studies | 12 | 2025 | 4824 | 0.410 |
Why?
|
Cell Culture Techniques | 3 | 2024 | 281 | 0.410 |
Why?
|
Asthma | 3 | 2008 | 756 | 0.400 |
Why?
|
Disease Outbreaks | 4 | 2014 | 320 | 0.370 |
Why?
|
Hospital Mortality | 7 | 2024 | 1026 | 0.360 |
Why?
|
Respiratory Syncytial Virus, Human | 2 | 2023 | 207 | 0.350 |
Why?
|
Orthomyxoviridae | 4 | 2014 | 51 | 0.350 |
Why?
|
Fever | 1 | 2013 | 299 | 0.350 |
Why?
|
Attitude of Health Personnel | 2 | 2013 | 677 | 0.350 |
Why?
|
Health Status Disparities | 1 | 2013 | 228 | 0.350 |
Why?
|
Asymptomatic Infections | 3 | 2025 | 34 | 0.350 |
Why?
|
Critical Illness | 2 | 2023 | 601 | 0.300 |
Why?
|
Delivery of Health Care | 3 | 2023 | 616 | 0.300 |
Why?
|
Patient Acuity | 3 | 2025 | 66 | 0.290 |
Why?
|
Antiviral Agents | 4 | 2022 | 767 | 0.290 |
Why?
|
Hemagglutinin Glycoproteins, Influenza Virus | 2 | 2024 | 59 | 0.260 |
Why?
|
Retropharyngeal Abscess | 2 | 1996 | 7 | 0.250 |
Why?
|
Administration, Intranasal | 7 | 2010 | 132 | 0.250 |
Why?
|
Real-Time Polymerase Chain Reaction | 4 | 2015 | 506 | 0.250 |
Why?
|
Respiration, Artificial | 3 | 2023 | 473 | 0.230 |
Why?
|
Sentinel Surveillance | 2 | 2024 | 19 | 0.220 |
Why?
|
Respiratory Syncytial Virus Vaccines | 1 | 2025 | 70 | 0.220 |
Why?
|
Treatment Outcome | 14 | 2025 | 12412 | 0.220 |
Why?
|
Presenteeism | 2 | 2023 | 2 | 0.220 |
Why?
|
Bias | 1 | 2024 | 133 | 0.220 |
Why?
|
Alkanesulfonic Acids | 1 | 2023 | 10 | 0.220 |
Why?
|
Respiratory Tract Diseases | 2 | 2020 | 75 | 0.210 |
Why?
|
Drug Utilization | 2 | 2015 | 161 | 0.210 |
Why?
|
Molecular Diagnostic Techniques | 2 | 2015 | 153 | 0.210 |
Why?
|
Acute Disease | 5 | 2018 | 1111 | 0.210 |
Why?
|
Fluorocarbons | 1 | 2023 | 56 | 0.210 |
Why?
|
Environmental Pollutants | 1 | 2023 | 68 | 0.210 |
Why?
|
Self Report | 4 | 2023 | 517 | 0.200 |
Why?
|
RNA, Viral | 5 | 2023 | 538 | 0.190 |
Why?
|
Venous Thromboembolism | 1 | 2025 | 167 | 0.190 |
Why?
|
Intention | 1 | 2022 | 93 | 0.190 |
Why?
|
Bronchial Hyperreactivity | 1 | 2001 | 38 | 0.190 |
Why?
|
Reverse Transcriptase Polymerase Chain Reaction | 5 | 2018 | 1290 | 0.190 |
Why?
|
Health Knowledge, Attitudes, Practice | 2 | 2025 | 854 | 0.190 |
Why?
|
Immunoglobulin G | 1 | 2024 | 777 | 0.190 |
Why?
|
Firefighters | 1 | 2022 | 32 | 0.190 |
Why?
|
Age Factors | 8 | 2020 | 2827 | 0.180 |
Why?
|
Reminder Systems | 1 | 2001 | 60 | 0.180 |
Why?
|
Middle East Respiratory Syndrome Coronavirus | 1 | 2021 | 22 | 0.180 |
Why?
|
Carrier State | 1 | 2021 | 76 | 0.180 |
Why?
|
Liver Diseases | 1 | 2025 | 368 | 0.180 |
Why?
|
Vaccination Coverage | 4 | 2023 | 35 | 0.180 |
Why?
|
Research Design | 1 | 2025 | 695 | 0.180 |
Why?
|
Coinfection | 1 | 2022 | 172 | 0.170 |
Why?
|
Organ Transplantation | 1 | 2022 | 168 | 0.170 |
Why?
|
Sick Leave | 1 | 2020 | 5 | 0.170 |
Why?
|
Hospitals | 4 | 2024 | 398 | 0.170 |
Why?
|
Viral Vaccines | 1 | 2023 | 337 | 0.170 |
Why?
|
Severity of Illness Index | 5 | 2022 | 2917 | 0.170 |
Why?
|
Antigenic Variation | 1 | 2020 | 39 | 0.170 |
Why?
|
Mycobacterium marinum | 1 | 1999 | 1 | 0.160 |
Why?
|
Oregon | 3 | 2014 | 9 | 0.160 |
Why?
|
Cheek | 1 | 1999 | 27 | 0.160 |
Why?
|
Incidence | 6 | 2025 | 3154 | 0.160 |
Why?
|
Immunity, Herd | 4 | 2024 | 12 | 0.160 |
Why?
|
Vaccines | 1 | 2024 | 366 | 0.160 |
Why?
|
Mycobacterium Infections, Nontuberculous | 1 | 1999 | 46 | 0.150 |
Why?
|
Drug Prescriptions | 2 | 2018 | 221 | 0.150 |
Why?
|
Body Mass Index | 1 | 2024 | 1568 | 0.150 |
Why?
|
Specimen Handling | 2 | 2022 | 142 | 0.150 |
Why?
|
Inappropriate Prescribing | 1 | 2018 | 41 | 0.150 |
Why?
|
Abscess | 1 | 1999 | 137 | 0.140 |
Why?
|
Pregnancy Complications, Infectious | 1 | 2022 | 455 | 0.140 |
Why?
|
Antibody Specificity | 2 | 2013 | 204 | 0.140 |
Why?
|
Enterococcus faecalis | 1 | 1997 | 47 | 0.140 |
Why?
|
Immunization Schedule | 3 | 2022 | 102 | 0.140 |
Why?
|
Gram-Positive Bacterial Infections | 1 | 1997 | 76 | 0.140 |
Why?
|
Laboratories | 3 | 2021 | 81 | 0.130 |
Why?
|
Mental Disorders | 1 | 2024 | 829 | 0.130 |
Why?
|
Texas | 6 | 2013 | 3589 | 0.130 |
Why?
|
Office Visits | 2 | 2015 | 77 | 0.130 |
Why?
|
Washington | 2 | 2013 | 32 | 0.130 |
Why?
|
Diagnostic Self Evaluation | 2 | 2013 | 21 | 0.130 |
Why?
|
Accidents, Home | 1 | 1996 | 9 | 0.130 |
Why?
|
Pulmonary Disease, Chronic Obstructive | 1 | 2023 | 604 | 0.130 |
Why?
|
Foot Injuries | 1 | 1996 | 7 | 0.130 |
Why?
|
Mediastinal Emphysema | 1 | 1996 | 11 | 0.130 |
Why?
|
Pneumonia, Aspiration | 1 | 1996 | 18 | 0.130 |
Why?
|
Medication Errors | 1 | 2018 | 187 | 0.130 |
Why?
|
Cost of Illness | 1 | 2017 | 252 | 0.130 |
Why?
|
Immunization | 3 | 2023 | 308 | 0.120 |
Why?
|
Antibodies, Bacterial | 1 | 1997 | 390 | 0.120 |
Why?
|
Time Factors | 5 | 2025 | 6345 | 0.120 |
Why?
|
Efficiency | 1 | 2015 | 62 | 0.120 |
Why?
|
Antibodies, Neutralizing | 3 | 2025 | 470 | 0.120 |
Why?
|
Neutrophils | 1 | 1997 | 381 | 0.120 |
Why?
|
Surveys and Questionnaires | 5 | 2022 | 3741 | 0.120 |
Why?
|
Anti-Bacterial Agents | 4 | 2020 | 2433 | 0.110 |
Why?
|
Immunity, Humoral | 2 | 2024 | 71 | 0.110 |
Why?
|
Osteomyelitis | 1 | 1996 | 208 | 0.110 |
Why?
|
Clostridium Infections | 1 | 1996 | 245 | 0.100 |
Why?
|
Risk Factors | 6 | 2025 | 10331 | 0.100 |
Why?
|
Anemia, Sickle Cell | 1 | 1996 | 331 | 0.100 |
Why?
|
Streptococcal Infections | 1 | 1995 | 240 | 0.100 |
Why?
|
Logistic Models | 3 | 2025 | 1815 | 0.100 |
Why?
|
Practice Patterns, Physicians' | 2 | 2018 | 735 | 0.100 |
Why?
|
Schools | 1 | 2014 | 219 | 0.100 |
Why?
|
Hydroxymethylglutaryl-CoA Reductase Inhibitors | 1 | 2019 | 734 | 0.100 |
Why?
|
Hepatitis A Antibodies | 1 | 2011 | 9 | 0.100 |
Why?
|
Hepatitis A Vaccines | 1 | 2011 | 10 | 0.090 |
Why?
|
Chickenpox Vaccine | 1 | 2011 | 13 | 0.090 |
Why?
|
Measles-Mumps-Rubella Vaccine | 1 | 2011 | 14 | 0.090 |
Why?
|
Odds Ratio | 3 | 2020 | 1260 | 0.090 |
Why?
|
Health Status | 1 | 2013 | 377 | 0.090 |
Why?
|
History, 21st Century | 3 | 2017 | 264 | 0.090 |
Why?
|
Bayes Theorem | 2 | 2022 | 285 | 0.080 |
Why?
|
Heart Failure | 1 | 2023 | 2299 | 0.080 |
Why?
|
Oxygen | 2 | 2023 | 557 | 0.080 |
Why?
|
Reference Standards | 2 | 2021 | 236 | 0.080 |
Why?
|
Genetic Variation | 1 | 2016 | 1502 | 0.080 |
Why?
|
Sex Factors | 1 | 2013 | 1289 | 0.080 |
Why?
|
RNA | 2 | 2023 | 570 | 0.080 |
Why?
|
Nose | 2 | 2020 | 94 | 0.070 |
Why?
|
Respiratory Sounds | 1 | 2008 | 70 | 0.070 |
Why?
|
Oropharynx | 2 | 2020 | 34 | 0.070 |
Why?
|
Comorbidity | 2 | 2019 | 1537 | 0.070 |
Why?
|
Parents | 2 | 2024 | 1026 | 0.060 |
Why?
|
Chronic Disease | 2 | 2022 | 1201 | 0.060 |
Why?
|
Epitopes, B-Lymphocyte | 1 | 2025 | 31 | 0.060 |
Why?
|
Drainage | 2 | 1996 | 259 | 0.050 |
Why?
|
Immunologic Memory | 1 | 2025 | 190 | 0.050 |
Why?
|
Risk | 2 | 2017 | 758 | 0.050 |
Why?
|
Propensity Score | 1 | 2025 | 222 | 0.050 |
Why?
|
Respiratory Syncytial Viruses | 1 | 2024 | 147 | 0.050 |
Why?
|
Advisory Committees | 1 | 2024 | 152 | 0.050 |
Why?
|
RNA-Directed DNA Polymerase | 1 | 2022 | 46 | 0.050 |
Why?
|
Nucleoproteins | 1 | 2022 | 25 | 0.050 |
Why?
|
Dyspnea | 1 | 2024 | 152 | 0.050 |
Why?
|
Community-Acquired Infections | 1 | 2005 | 241 | 0.050 |
Why?
|
RNA, Messenger, Stored | 1 | 2022 | 7 | 0.050 |
Why?
|
Fatigue | 1 | 2024 | 190 | 0.050 |
Why?
|
Police | 1 | 2022 | 9 | 0.050 |
Why?
|
Perception | 1 | 2024 | 220 | 0.050 |
Why?
|
B-Lymphocytes | 1 | 2025 | 535 | 0.050 |
Why?
|
Risk Assessment | 2 | 2021 | 3468 | 0.050 |
Why?
|
Drugs, Investigational | 1 | 2002 | 22 | 0.050 |
Why?
|
Epitopes | 1 | 2024 | 433 | 0.050 |
Why?
|
Arizona | 1 | 2021 | 23 | 0.050 |
Why?
|
Antibodies | 1 | 2023 | 374 | 0.050 |
Why?
|
Immunocompetence | 1 | 2022 | 32 | 0.050 |
Why?
|
Neutralization Tests | 1 | 2022 | 235 | 0.050 |
Why?
|
Computer Simulation | 1 | 2025 | 653 | 0.050 |
Why?
|
Saliva | 1 | 2022 | 114 | 0.050 |
Why?
|
Nasopharynx | 2 | 2013 | 79 | 0.050 |
Why?
|
Child, Hospitalized | 1 | 2022 | 73 | 0.050 |
Why?
|
Safety | 1 | 2002 | 217 | 0.050 |
Why?
|
Documentation | 1 | 2022 | 113 | 0.050 |
Why?
|
Sample Size | 1 | 2021 | 86 | 0.040 |
Why?
|
Proteomics | 1 | 2024 | 502 | 0.040 |
Why?
|
Longitudinal Studies | 1 | 2025 | 1329 | 0.040 |
Why?
|
Absenteeism | 2 | 2014 | 20 | 0.040 |
Why?
|
Demography | 1 | 2021 | 240 | 0.040 |
Why?
|
Whole Genome Sequencing | 1 | 2022 | 281 | 0.040 |
Why?
|
Transplant Recipients | 1 | 2022 | 219 | 0.040 |
Why?
|
Diagnosis, Differential | 2 | 1996 | 1899 | 0.040 |
Why?
|
Sensitivity and Specificity | 2 | 2016 | 2058 | 0.040 |
Why?
|
Syndrome | 1 | 2022 | 1121 | 0.040 |
Why?
|
Workplace | 1 | 2020 | 70 | 0.040 |
Why?
|
Retrospective Studies | 3 | 2024 | 16389 | 0.040 |
Why?
|
Pharyngitis | 1 | 2018 | 32 | 0.040 |
Why?
|
Patient Acceptance of Health Care | 1 | 2022 | 427 | 0.040 |
Why?
|
School Health Services | 2 | 2010 | 99 | 0.040 |
Why?
|
Public Health Surveillance | 1 | 2018 | 38 | 0.040 |
Why?
|
Blood Bactericidal Activity | 1 | 1997 | 17 | 0.040 |
Why?
|
Opsonin Proteins | 1 | 1997 | 20 | 0.040 |
Why?
|
Patient Readmission | 1 | 2021 | 385 | 0.040 |
Why?
|
Medical Records | 1 | 2018 | 192 | 0.040 |
Why?
|
Immunologic Factors | 1 | 2019 | 174 | 0.040 |
Why?
|
Intensive Care Units | 1 | 2021 | 493 | 0.040 |
Why?
|
Complement System Proteins | 1 | 1997 | 58 | 0.040 |
Why?
|
Frailty | 1 | 2019 | 104 | 0.030 |
Why?
|
Clinical Trials as Topic | 1 | 2002 | 1104 | 0.030 |
Why?
|
Inpatients | 1 | 2021 | 500 | 0.030 |
Why?
|
Immunization Programs | 1 | 2017 | 63 | 0.030 |
Why?
|
Pharynx | 1 | 2017 | 66 | 0.030 |
Why?
|
Sinusitis | 1 | 2018 | 116 | 0.030 |
Why?
|
Phagocytosis | 1 | 1997 | 170 | 0.030 |
Why?
|
Antimicrobial Stewardship | 1 | 2018 | 84 | 0.030 |
Why?
|
Prevalence | 1 | 2023 | 2467 | 0.030 |
Why?
|
Pregnancy | 2 | 2022 | 7223 | 0.030 |
Why?
|
Dose-Response Relationship, Drug | 1 | 2020 | 1698 | 0.030 |
Why?
|
Genetic Drift | 1 | 2016 | 21 | 0.030 |
Why?
|
Cross-Sectional Studies | 1 | 2025 | 3440 | 0.030 |
Why?
|
Tibia | 1 | 1996 | 70 | 0.030 |
Why?
|
Fusarium | 1 | 1996 | 11 | 0.030 |
Why?
|
Electronic Health Records | 1 | 2023 | 722 | 0.030 |
Why?
|
Bacillus | 1 | 1996 | 35 | 0.030 |
Why?
|
Amphotericin B | 1 | 1996 | 90 | 0.030 |
Why?
|
Health Services | 2 | 2006 | 71 | 0.030 |
Why?
|
Topography, Medical | 1 | 2015 | 6 | 0.030 |
Why?
|
Antigens, Bacterial | 1 | 1997 | 314 | 0.030 |
Why?
|
Disease Progression | 1 | 2021 | 2077 | 0.030 |
Why?
|
Cross Protection | 1 | 2014 | 7 | 0.030 |
Why?
|
Polymerase Chain Reaction | 1 | 2018 | 1586 | 0.030 |
Why?
|
Linear Models | 1 | 2016 | 686 | 0.030 |
Why?
|
Escherichia coli Infections | 1 | 1996 | 189 | 0.030 |
Why?
|
Infant, Newborn | 2 | 2017 | 8240 | 0.030 |
Why?
|
Radiography | 1 | 1996 | 823 | 0.030 |
Why?
|
Antifungal Agents | 1 | 1996 | 291 | 0.030 |
Why?
|
Nasal Cavity | 1 | 2013 | 50 | 0.030 |
Why?
|
Self-Assessment | 1 | 2013 | 66 | 0.030 |
Why?
|
Obesity | 1 | 2024 | 2252 | 0.030 |
Why?
|
Drug Therapy, Combination | 1 | 1996 | 1175 | 0.020 |
Why?
|
Activities of Daily Living | 1 | 2014 | 407 | 0.020 |
Why?
|
Combined Modality Therapy | 1 | 1995 | 1244 | 0.020 |
Why?
|
Recurrence | 1 | 1995 | 1420 | 0.020 |
Why?
|
Follow-Up Studies | 1 | 2020 | 5185 | 0.020 |
Why?
|
Drug Interactions | 1 | 2011 | 257 | 0.020 |
Why?
|
High-Throughput Nucleotide Sequencing | 1 | 2016 | 880 | 0.020 |
Why?
|
Vaccines, Subunit | 1 | 2010 | 66 | 0.020 |
Why?
|
Age Distribution | 1 | 2010 | 419 | 0.020 |
Why?
|
Placebos | 1 | 2010 | 241 | 0.020 |
Why?
|
Internet | 1 | 2012 | 376 | 0.020 |
Why?
|
Skin Diseases | 1 | 2010 | 130 | 0.020 |
Why?
|
Drug-Related Side Effects and Adverse Reactions | 1 | 2010 | 259 | 0.020 |
Why?
|
Injections, Intramuscular | 1 | 2007 | 194 | 0.020 |
Why?
|
Tomography, X-Ray Computed | 1 | 1995 | 2107 | 0.020 |
Why?
|
Double-Blind Method | 1 | 2010 | 1638 | 0.020 |
Why?
|
Family Health | 1 | 2006 | 259 | 0.020 |
Why?
|
Michigan | 1 | 2005 | 42 | 0.010 |
Why?
|
Japan | 1 | 2005 | 133 | 0.010 |
Why?
|
Registries | 1 | 2010 | 1435 | 0.010 |
Why?
|